•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Air Combat Command and Hypori Launch First Secure Messaging Implementation to Modernize Air Force Mobile Communications
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026
Honda to Begin Sales of Super-ONE Compact EV
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform
GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research
Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Stellantis-backed ACC drops plans for Italian, German gigafactories, union says
InventHelp Inventor Develops New Toothbrush/Vape Pen (ACC-486)
Aker Carbon Capture: Second-Quarter and Half-year Results 2025
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway
ACC.25: Bayer Presents New Investigational Heart Failure Data and Continued Portfolio Research in Chronic Kidney Disease in Type 2 Diabetes